February 12, 2018 / 1:09 PM / 5 months ago

BRIEF-Pfizer says U.S., EU And Japan Health Authorities Accept Lorlatinib For Review

Reuters Staff

1 Min Read

Feb 12 (Reuters) - Pfizer Inc:

* U.S., EU AND JAPAN HEALTH AUTHORITIES ACCEPT REGULATORY SUBMISSIONS FOR REVIEW OF PFIZER’S THIRD-GENERATION ALK INHIBITOR LORLATINIB

* PFIZER INC - U.S. NEW DRUG APPLICATION FOR LORLATINIB GRANTED FDA PRIORITY REVIEW Source text for Eikon: Further company coverage:

0 : 0